OCS Oculis Holding AG
USHealthcareAs of 2026-08-24
Why OCS matters now
Oculis Holding AG (OCS) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.18 with +0.73% on the session and $753.5M in market capitalization; recent performance reads 1-month -59.87% and YTD -43.82%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-29.5M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.1%.
The latest indexable market news headline is "First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.72
P/S
1026.31
EV/EBITDA
-4.84
DCF Value
$1.89
FCF Yield
-12.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-2889.4%
Operating Margin
-16741.0%
Net Margin
-18861.3%
ROE
-57.1%
ROA
-39.1%
ROIC
-42.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-29.5M | $-0.50 |
| Q4 2025 | $0.00 | $-23.3M | $-0.42 |
| FY 2025 | $0.00 | $-94.5M | $-1.81 |
| Q3 2025 | $243.0K | $-16.9M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$39.40
Target (Median)
$38.00
Target Range
$26.00 - $50.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CH
Exchange
—
Beta
0.13
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.